Cantor Fitzgerald Maintains Neutral on Amgen, Raises Price Target to $440
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice TargetHot
Cantor Fitzgerald analyst Carter Gould maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $400 to $440.
Cantor Fitzgerald analyst Carter Gould maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $400 to $440.